Regional overviews

celebrating 20 years Sub-Saharan Africa

STATISTICS  
Number of products launched: 10 (2017: 11)#
IMS value of pipeline as at 30 June 2018 anticipated to be launched in:  
0 – 2 years USD119 million
3 – 5 years USD250 million
Number of product recalls: 8 (2017: 1)
Average staff turnover: 9,4% (2017: 13%)
Number of work-related fatalities: 0 (2017: 0)
Number of permanent employees:  
Number of permanent employees:  

* South Africa only, rest of SSA not covered by IMS.
# The number of product launches has been restated as a result of the refinement of the product launch definition

 

The SSA business provides a diverse basket of branded, generic, OTC and consumer health products which are supplied to both the private and public sectors primarily in South Africa. Our presence outside of South Africa is mainly in Namibia, Botswana, Tanzania, Kenya, Nigeria, Ghana and Uganda.

KEY COUNTRIES

Botswana, Kenya, Namibia, South Africa, Tanzania

Contribution to Group revenue

Revenue - R'million 2018 2017 (CER) % change
Commercial Pharmaceuticals 8 127 7 402 10%
Regional Brands 7 876 7 124 11
Anaesthetics 143 145 (1)
Thrombosis 9 7 29
High Potency & Cytotoxics 99 126 (21)
Nutritionals 1 017 977 4
Manufacturing 864 1 192 (28)
– API 332 217 53
– FDF 532 975 (45)
Total 10 008 9 571 5

Note: Commercial Pharmaceuticals revenue by customer geography and manufacturing revenue by place of manufacture

 
  • The South African private pharmaceutical sector was valued at R42,9 billion for the year ended 30 June 2018.
  • Aspen is ranked as the number one pharmaceutical company in the South African private sector with a 12,9% share by value.
  • About one in every five scripts dispensed by South African pharmacists is for an Aspen product, as recorded by ImpactRx.
  • In South Africa, six out of the top 25 brands in the private sector for the year ended 30 June 2018 were Aspen products.

  • Source: May 2018 IMS
  • Aspen has a strong presence in East Africa through Beta Kenya and Shelys Tanzania.